| RPP # | Requirement Topic | Description | Requiring Office | Submission Due Date |
|---|---|---|---|---|
| RPP-24-02-OralVx (09/09/2024) | NextGen Oral Formulation Vaccines for COVID-19 | The purpose of this project is to advance oral vaccine platforms and technologies into a proof-of-concept Phase 1 clinical trial, improve our understanding of their potential, and to provide better COVID-19 solutions and bolster preparedness and response against future health security threats. | 1 November 2024 by 1pm Eastern | |
| RPP-24-08-mRNALongTerm (08/30/2024) | Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability | BARDA seeks to establish a long-term partnership centered around the development of a broad preparedness and response capability that can be rapidly and flexibly leveraged toward vaccine development for pandemic influenza or other priority pathogen threats. BARDA envisions an initial focus on influenza mRNA vaccine development that complements existing pandemic influenza response capabilities. As the program matures beyond licensure of influenza vaccines, there will be increased focus on continually ‘exercising’ preparedness and response efforts at small scale to ensure readiness to rapidly pivot to address pandemic influenza or any other emerging infectious disease that poses a threat. The penultimate goal for this program is to serve as a critical component of the Nation’s pandemic response for influenza and any other emerging infectious diseases, collaboratively working with BARDA to develop multiple products using a single, flexible platform capability. | IEID | 16 December 2024, by 1pm Eastern |
| RPP # (Date) | Requirement Topic | Closed Date |
|---|---|---|
| RPP-24-02-ODM (08/13/2024) | On-Demand Manufacturing | 9/25/2024 |
| RPP-24-03-SmMol (08/05/2024) | COVID-19 Small Molecule Therapeutics for PrEP | 9/20/2024 |
| RPP-24-07-CentralIEIDLab (06/14/2024) | Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services | 07/15/2024 |
| RPP-24-06-DxR2 (3/27/2024) | Biothreat Diagnostic Rapid Response | 5/17/2024 |
| RPP-24-03-Treatment (02/21/2024) | Project NextGen: Therapeutics | 5/13/2024 |
| RPP-24-05-NGClinMfg (01/16/2024) | Project NextGen: Innovation in Clinical Manufacturing of COVID-19 Vaccines | 04/19/2024 |
| RPP-24-04-NGVxStats (2/23/2024) | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis | 03/27/2024 |
| RPP-24-04-NGVxAssays (2/15/2024) | NextGen Vaccines: Immune Assays | 3/22/2024 |
| RPP-24-02-Retail (2/2/2024) | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus | 03/20/2024 |
| RPP-24-03-PrEP (11/30/2023) | COVID-19 Monoclonal Antibody Therapeutics for PrEP | 01/19/2024 |
| RPP-24-02-HomeFocus (11/30/2023) | Enabling Technology – Decentralized Clinical Trial – Home Focus | 01/19/2024 |
| RPP-24-04-NGVx (11/30/2023) | NextGen Vaccinations: Phase 2B Clinical Trial Execution | 01/10/2024 |
RPP-24-01-mRNA | Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine | 12/4/2023 |
